Compare WKEY & CING Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | WKEY | CING |
|---|---|---|
| Founded | 1999 | 2012 |
| Country | Switzerland | United States |
| Employees | 102 | 13 |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 83.5M | 93.1M |
| IPO Year | N/A | N/A |
| Metric | WKEY | CING |
|---|---|---|
| Price | $7.51 | $5.26 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 2 |
| Target Price | $10.50 | ★ $34.50 |
| AVG Volume (30 Days) | 90.1K | ★ 573.5K |
| Earning Date | 01-28-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $31.22 | N/A |
| Revenue Next Year | $91.39 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $3.26 | $3.20 |
| 52 Week High | $19.80 | $11.89 |
| Indicator | WKEY | CING |
|---|---|---|
| Relative Strength Index (RSI) | 61.93 | 37.13 |
| Support Level | $7.26 | $3.62 |
| Resistance Level | $7.56 | $6.85 |
| Average True Range (ATR) | 0.47 | 0.52 |
| MACD | 0.15 | -0.14 |
| Stochastic Oscillator | 94.78 | 0.00 |
WISeKey International Holding Ltd is a cybersecurity company focused on delivering integrated security solutions for the Internet of Things and digital identity ecosystems. It integrates secure semiconductors, cybersecurity software, and a globally recognized Root of Trust (RoT) into products and services that protect users, devices, data and transactions in the internet-connected world. It has two business segments. The IoT segment, which is the key revenue driver, generates revenue from the sale of semiconductor's secure chips. The mPKI segment generates revenues from Digital Certificates, It derives maximum revenue from IoT segment.
Cingulate Inc is a clinical-stage biopharmaceutical company utilizing its proprietary precision timed-release drug delivery platform to build and advance a pipeline of next-generation pharmaceutical products designed to improve the lives of patients suffering from frequently diagnosed conditions characterized by burdensome daily dosing regimens and suboptimal treatment outcomes. The company focuses on the treatment of Attention Deficit/Hyperactivity Disorder (ADHD) and anxiety, and identifying and evaluating additional therapeutic area to use PTR technology to develop future product candidates.